MCID: ACT075
MIFTS: 56

Acute Myocardial Infarction

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Acute Myocardial Infarction

MalaCards integrated aliases for Acute Myocardial Infarction:

Name: Acute Myocardial Infarction 12 54 15 17 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9408
ICD9CM 34 410
NCIt 50 C35204
SNOMED-CT 67 155304006
ICD10 32 I21 I21.9
UMLS 71 C0155626

Summaries for Acute Myocardial Infarction

MalaCards based summary : Acute Myocardial Infarction is related to myocardial infarction and cardiogenic shock, and has symptoms including angina pectoris and chest pain. An important gene associated with Acute Myocardial Infarction is MIR499A (MicroRNA 499a), and among its related pathways/superpathways is Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Pravastatin and Bivalirudin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, endothelial and heart, and related phenotype is cardiovascular system.

Related Diseases for Acute Myocardial Infarction

Diseases in the Myocardial Infarction family:

Myocardial Infarction 2 Posterior Myocardial Infarction
Acute Myocardial Infarction

Diseases related to Acute Myocardial Infarction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 myocardial infarction 33.2 TNNT2 TNNI3 SELP PLAT PIK3C2A NPPB
2 cardiogenic shock 33.1 PLAT NPPB
3 cardiac rupture 32.9 PLAT CRP
4 acute anterolateral myocardial infarction 32.8 PIK3C2A ACE
5 angina pectoris 32.6 TNNI3 PLAT PIK3C2A NPPB MB F3
6 ischemia 32.6 SELP PLAT PIK3C2A NPPB MB FABP3
7 intermediate coronary syndrome 32.5 TNNT2 TNNI3 SELP PLAT PIK3C2A MB
8 cardiac arrest 32.5 TNNT2 TNNI3 PIK3C2A NPPB ACE
9 inferior myocardial infarction 32.4 TNNI3 PLAT PIK3C2A NPPB ACE
10 coronary thrombosis 32.4 SELP PLAT F3 CRP
11 left bundle branch hemiblock 32.3 TNNT2 TNNI3 PIK3C2A NPPB CRP ACE
12 congestive heart failure 32.3 TNNT2 TNNI3 PIK3C2A NPPB FABP3 CRP
13 coronary stenosis 32.3 TNNI3 PIK3C2A NPPB CRP ACE
14 mitral valve insufficiency 32.3 TNNT2 TNNI3 PIK3C2A NPPB CRP ACE
15 anterolateral myocardial infarction 32.3 PLAT NPPB ACE
16 arteries, anomalies of 32.2 TNNI3 MIR499A F3 CRP ACE
17 myocarditis 32.2 TNNI3 PIK3C2A NPPB MB ACE
18 pulmonary edema 32.2 TNNT2 TNNI3 PIK3C2A NPPB CRP ACE
19 atrial fibrillation 32.2 SELP PLAT NPPB CRP ACE
20 pericarditis 32.2 TNNT2 TNNI3 NPPB CRP ACE
21 hemopericardium 32.2 TNNI3 F3 CRP
22 right bundle branch block 32.1 TNNI3 NPPB ACE
23 atrial standstill 1 32.1 TNNT2 TNNI3 NPPB ACE
24 coronary artery vasospasm 32.1 TNNI3 PIK3C2A CRP ACE
25 peripheral vascular disease 32.0 SELP PLAT F3 CRP ACE
26 pericardial effusion 32.0 TNNI3 PIK3C2A NPPB F3 CRP ACE
27 chronic kidney disease 32.0 TNNT2 TNNI3 NPPB F3 CRP ACE
28 vascular disease 32.0 SELP PLAT NPPB F3 CRP ACE
29 aortic dissection 32.0 TNNT2 CRP ACE
30 cerebrovascular disease 32.0 SELP PLAT NPPB CRP ACE
31 pneumonia 32.0 PIK3C2A MB CRP ACE
32 atrioventricular block 31.9 TNNI3 PIK3C2A NPPB MHRT ACE
33 cardiac tamponade 31.9 TNNI3 PLAT PIK3C2A NPPB F3 CRP
34 respiratory failure 31.9 PIK3C2A NPPB F3 CRP ACE
35 antiphospholipid syndrome 31.9 SELP PLAT F3 CRP
36 anteroseptal myocardial infarction 31.9 PIK3C2A MB ACE
37 endocarditis 31.8 TNNI3 PLAT PIK3C2A CRP
38 pulmonary embolism 31.8 TNNT2 TNNI3 PLAT NPPB MB FABP3
39 lipoprotein quantitative trait locus 31.8 TNNT2 TNNI3 SELP PLAT PIK3C2A NPPB
40 sleep apnea 31.8 NPPB CRP ACE
41 pulmonary disease, chronic obstructive 31.8 NPPB MB CRP ACE
42 diabetes mellitus 31.8 TNNT2 TNNI3 SELP PLAT PIK3C2A NPPB
43 acute myocarditis 31.8 TNNT2 TNNI3 NPPB MB CRP ACE
44 purpura 31.8 F3 CRP ACE
45 myocardial stunning 31.8 TNNT2 TNNI3 ACE
46 stroke, ischemic 31.7 SELP PLAT NPPB MB F3 CRP
47 infective endocarditis 31.7 TNNT2 TNNI3 CRP
48 atherosclerosis susceptibility 31.7 SELP F3 CRP CDKN2B-AS1 ACE
49 covid-19 31.6 TNNI3 NPPB F3 ACE
50 lateral myocardial infarction 31.6 TNNI3 PIK3C2A ACE

Comorbidity relations with Acute Myocardial Infarction via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Kidney Disease Mitral Valve Disease
Peripheral Vascular Disease Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Acute Myocardial Infarction:



Diseases related to Acute Myocardial Infarction

Symptoms & Phenotypes for Acute Myocardial Infarction

UMLS symptoms related to Acute Myocardial Infarction:


angina pectoris, chest pain

MGI Mouse Phenotypes related to Acute Myocardial Infarction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.32 ACE CRP F3 FABP3 MB PIK3C2A

Drugs & Therapeutics for Acute Myocardial Infarction

Drugs for Acute Myocardial Infarction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
3
Thrombin Approved, Investigational Phase 4
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
Famotidine Approved Phase 4 76824-35-6 3325
6
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
7
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Atorvastatin Approved Phase 4 134523-00-5 60823
10
tannic acid Approved Phase 4 1401-55-4
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
13
Abciximab Approved Phase 4 143653-53-6
14
Streptokinase Approved, Investigational Phase 4 9002-01-1
15
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
16
Tirofiban Approved Phase 4 144494-65-5 60947
17
Lenograstim Approved, Investigational Phase 4 135968-09-1
18
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
19
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
20
Eplerenone Approved Phase 4 107724-20-9 150310 443872
21 Apricot Approved Phase 4
22
Edaravone Approved, Investigational Phase 4 89-25-8 70335
23
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
24
Insulin lispro Approved Phase 4 133107-64-9
25
Insulin glargine Approved Phase 4 160337-95-1
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Aminophylline Approved Phase 4 317-34-0 9433
28
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
29
Norepinephrine Approved Phase 4 51-41-2 439260
30
Cangrelor Approved Phase 4 163706-06-7 9854012
31
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
32
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
33
Bisoprolol Approved Phase 4 66722-44-9 2405
34
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
35
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
36
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
37
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
38
Ticagrelor Approved Phase 4 274693-27-5 9871419
39
Ezetimibe Approved Phase 4 163222-33-1 150311
40
Warfarin Approved Phase 4 81-81-2 6691 54678486
41
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
42
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
43
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
44
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
45
Nitric Oxide Approved Phase 4 10102-43-9 145068
46
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
47
Tenecteplase Approved Phase 4 191588-94-0
48
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
50 Molgramostim Investigational Phase 4 99283-10-0

Interventional clinical trials:

(show top 50) (show all 675)
# Name Status NCT ID Phase Drugs
1 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
2 Effect of Gradual Reperfusion on Myocardial Edema and Coronary Microvascular Integrity in Patients Undergoing Primary Percutaneous Coronary Intervention Unknown status NCT02732080 Phase 4
3 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl Unknown status NCT00688922 Phase 4 Pravastatin
4 Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) Unknown status NCT02428374 Phase 4 Rosuvastatin plus clopidogrel;Rosuvastatin plus ticagrelor;Simvastatin plus clopidogrel;Simvastatin plus ticagrelor
5 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
6 Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
7 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
8 Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study. Unknown status NCT01914055 Phase 4
9 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
10 Treating Acute MI Patients With Aggrastat on Their Way to Hospital Unknown status NCT00300833 Phase 4 Tirofiban
11 Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography Unknown status NCT01875835 Phase 4
12 Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine Unknown status NCT02281305 Phase 4 Colchicine
13 Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL) Unknown status NCT02170103 Phase 4 Microbubbles
14 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial Unknown status NCT00229515 Phase 4
15 Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction Unknown status NCT02512978 Phase 4 Levothyroxine
16 Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI Unknown status NCT00288210 Phase 4
17 A Randomized Clinical Trial Comparing Primary PCI and Post-thrombolysis PCI as Reperfusion Strategies in Patients With ST Segment Elevation Acute Myocardial Infarction Unknown status NCT02268669 Phase 4
18 Southwest German Interventional Study in Acute Myocardial Infarction III Completed NCT01124890 Phase 4
19 Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction Completed NCT00683111 Phase 4 esomeprazole 20 mg daily;famotidine 40 mg daily
20 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment
21 Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin Completed NCT01062516 Phase 4 esomeprazole 20 mg daily;famotidine 40 mg daily
22 Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism Completed NCT00915733 Phase 4 cilostazol;clopidogrel (Plavix);aspirin (Acetylsalicylic acid)
23 Cangrelor Administration Following Ticagrelor Loading vs Ticagrelor Loading Alone in ST Segment Elevation Myocardial Infarction Patients: A Randomized, Pharmacodynamic Study Completed NCT02943369 Phase 4 Ticagrelor 180 mg loading dose;Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min
24 A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study Completed NCT00986050 Phase 4 Abciximab
25 Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The ME"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion" (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial of Early Pre-reperfusion Metoprolol Administration in ST-segment Elevation Myocardial infarctionTOCARD-CNIC Trial. Completed NCT01311700 Phase 4 Injectable (i.v.) metoprolol tartrate (up to 15 mg).
26 Phase 4 Study of Application of Intracoronary Low Dose Streptokinase Complementary to Standard Percutaneous Coronary Intervention in Patients With ST Elevation Acute Myocardial Infarction: Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction Completed NCT00627809 Phase 4 Streptokinase
27 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
28 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
29 Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial Completed NCT01696110 Phase 4 Bivalirudin;heparin;heparin plus tirofiban
30 Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in Patients With Acute ST-segment Elevation Myocardial Infarction; ICAT Trial Completed NCT01404507 Phase 4 Gp 2b 3a inhibitor
31 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial Completed NCT01377207 Phase 4
32 Bioresorbable Vascular Scaffold in Patient With ST Elevation Myocardial Infarction: a Randomized Comparison With Everolimus Eluting Stent Completed NCT02151929 Phase 4
33 The Effects of Facilitated Percutaeous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction Completed NCT00611169 Phase 4 tirofiban
34 Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction Completed NCT00302419 Phase 4 intracoronary infusion,
35 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
36 Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction Completed NCT01381185 Phase 4 Aspirin 200mg qd, Clopidogrel 2x75mg qd
37 Thrombectomy Before Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Improves Left Ventricular Function at 3 Months Completed NCT00288665 Phase 4
38 Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin Completed NCT00712894 Phase 4 Diltiazem;Verapamil;Nitroglycerin
39 Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction Completed NCT02627950 Phase 4 Morphinhydrochloricum;Metoclopramide;Ticagrelor;Isotonic sodium chloride
40 Individual-Patient-Data Pooled-Analysis Comparing Long Term Clinical Outcome in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention With or Without Prior Thrombectomy Completed NCT00766740 Phase 4
41 FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study Completed NCT00383136 Phase 4 tirofiban high-bolus dose regimen;Abciximab
42 Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. Completed NCT00257153 Phase 4
43 IRIS - Immediate Risk-stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK) Completed NCT00157768 Phase 4
44 A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction Completed NCT01050348 Phase 4 Atorvastatin calcium;Inactive Placebo
45 Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome Completed NCT01501110 Phase 4 N-acetylcysteine
46 Phase 4 Study of Atorvastatin 10mg vs. 40mg in Follow-up CFR in AMI Patients Completed NCT00536887 Phase 4 atorvastatin
47 Very Early Initiation of Treatment With Thrombolysis and Low Molecular Weight Heparin, Versus Abciximab and Low Molecular Weight Heparin Followed by Percutaneous Coronary Intervention, for Acute ST-Elevation Myocardial Infarction Completed NCT00806403 Phase 4 reteplase 10+10 U
48 Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction Completed NCT00882466 Phase 4 human recombinant erythropoietin
49 Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty Completed NCT00538317 Phase 4 tirofiban;tirofiban
50 Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD & GO Trial Completed NCT00882739 Phase 4 Clopidogrel 300 mg;Clopidogrel 600 mg;Clopidogrel 900 mg

Search NIH Clinical Center for Acute Myocardial Infarction

Genetic Tests for Acute Myocardial Infarction

Anatomical Context for Acute Myocardial Infarction

MalaCards organs/tissues related to Acute Myocardial Infarction:

40
Bone Marrow, Endothelial, Heart, Bone, Neutrophil, Kidney, Thyroid

Publications for Acute Myocardial Infarction

Articles related to Acute Myocardial Infarction:

(show top 50) (show all 30474)
# Title Authors PMID Year
1
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. 47
20921333 2010
2
Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. 54 61
20378999 2010
3
Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. 61 54
20435200 2010
4
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. 54 61
19662337 2010
5
Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. 54 61
20388121 2010
6
Left ventricular function and C-reactive protein levels in acute myocardial infarction. 61 54
20346306 2010
7
Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. 54 61
20140003 2010
8
[The significance of the changes in expressions of heat shock protein 70 and heme oxygenase-1 in the myocardium in patients died suddenly due to acute myocardial infarction]. 61 54
20170613 2010
9
Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. 54 61
20102882 2010
10
Noninvasive assessment of left ventricular filling pressure after acute myocardial infarction: a prospective study of the relative prognostic utility of clinical assessment, echocardiography, and B-type natriuretic peptide. 54 61
20102866 2010
11
Circulating p53 and cytochrome c levels in acute myocardial infarction patients. 54 61
19551350 2010
12
Admission creatine kinase as a prognostic marker in acute myocardial infarction. 54 61
20201171 2009
13
Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. 54 61
19809306 2009
14
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. 61 54
19410278 2009
15
Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction. 61 54
19558505 2009
16
TNF-alpha/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction. 61 54
19576194 2009
17
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. 61 54
19520708 2009
18
[Correlation between serum MMP-2 and MMP-9 in patients with acute myocardial infarction before and after PCI]. 54 61
19664397 2009
19
The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. 54 61
19637097 2009
20
Conjugation of biomolecules with magnetic protein microspheres for the assay of early biomarkers associated with acute myocardial infarction. 61 54
19555077 2009
21
Carboxylated magnetic microbead-assisted fluoroimmunoassay for early biomarkers of acute myocardial infarction. 61 54
19398193 2009
22
Association of C-reactive protein and HIV infection with acute myocardial infarction. 61 54
19387353 2009
23
The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: the role of inflammation. 54 61
18579226 2009
24
Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. 61 54
19570241 2009
25
Expressions of eNOS3 and Ve-cadherin in microvascular endothelium at 7-day of reperfused acute myocardial infarction. 61 54
19519369 2009
26
Superparamagnetic microsphere-assisted fluoroimmunoassay for rapid assessment of acute myocardial infarction. 61 54
19394809 2009
27
[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction]. 54 61
19927632 2009
28
[Study of association of platelet endothelial cell adhesion molecule-1 gene polymorphism with acute myocardial infarction]. 54 61
19570335 2009
29
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. 61 54
19346228 2009
30
Levels of serum deoxyribonuclease I activity on admission in patients with acute myocardial infarction can be useful in predicting left ventricular enlargement due to remodeling. 54 61
19304122 2009
31
Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction. 54 61
18571749 2009
32
[The relationship between plasma BNP level and the left ventricular dysfunction parameters in patients with acute myocardial infarction and it's value in diagonosing heart failure.]. 61 54
19781144 2009
33
[Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction]. 61 54
19341228 2009
34
Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. 61 54
18190989 2009
35
Factors associated with C-reactive protein at the early stage of acute myocardial infarction in men. 54 61
19130414 2009
36
Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. 54 61
18997620 2009
37
Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. 61 54
19246845 2009
38
The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. 54 61
18580060 2009
39
Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. 61 54
18038115 2008
40
[Plasma tissue factor and tissue factor pathway inhibitor levels in acute myocardial infarction patients with no-reflow during percutaneous coronary intervention]. 61 54
19102916 2008
41
[Comparative effect of streptokinase and alteplase on electrocardiogram and angiogram signs of myocardial reperfusion in ST segment elevation acute myocardial infarction]. 54 61
19069338 2008
42
Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. 61 54
18810578 2008
43
Impact of plaque rupture and elevated C-reactive protein on clinical outcome in patients with acute myocardial infarction: an intravascular ultrasound study. 54 61
18762670 2008
44
Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling. 61 54
18761267 2008
45
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. 47
18723672 2008
46
Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. 54 61
18766137 2008
47
A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. 54 61
17698228 2008
48
[Role of nuclear factor-KappaB in endothelial injury in acute myocardial infarction]. 54 61
18611340 2008
49
Late ventricular remodeling in non-reperfused acute myocardial infarction in humans is predicted by angiotensin II type 1 receptor density on blood platelets. 54 61
17651844 2008
50
Value of brain natriuretic peptide after acute myocardial infarction. 54 61
18524723 2008

Variations for Acute Myocardial Infarction

Copy number variations for Acute Myocardial Infarction from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210497 6 30400000 36600000 Amplification C4B Acute myocardial infarction

Expression for Acute Myocardial Infarction

LifeMap Discovery
Genes differentially expressed in tissues of Acute Myocardial Infarction patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 5.52 0.000
2 CXCL8 C-X-C motif chemokine ligand 8 Blood + 3.51 0.004
3 LEP leptin Heart + 3.45 0.011
4 ID1 inhibitor of DNA binding 1, HLH protein Blood + 3.18 0.007
Search GEO for disease gene expression data for Acute Myocardial Infarction.

Pathways for Acute Myocardial Infarction

Pathways related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.78 TNNT2 TNNI3 FABP3

GO Terms for Acute Myocardial Infarction

Cellular components related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 SELP PLAT NPPB MIR29A FABP3 F3
2 troponin complex GO:0005861 9.16 TNNT2 TNNI3
3 cardiac myofibril GO:0097512 8.96 TNNT2 TNNI3
4 cardiac Troponin complex GO:1990584 8.62 TNNT2 TNNI3

Biological processes related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heart contraction GO:0060047 9.16 TNNI3 ACE
2 negative regulation of ATPase activity GO:0032780 8.96 TNNT2 TNNI3
3 transition between fast and slow fiber GO:0014883 8.62 MIR499A MIR208B

Molecular functions related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 troponin C binding GO:0030172 8.62 TNNT2 TNNI3

Sources for Acute Myocardial Infarction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....